Skip to main content
Data show positive results for Boston Scientific's S-ICD

Midterm outcomes from a 1,000-patient, 42-site trial, published in the Journal of the American College of Cardiology, found the use of Boston Scientific's subcutaneous implantable cardioverter defibrillator continued to be effective and safe for treating patients with lethal ventricular arrhythmias at one year. The device demonstrated a 97.4% overall conversion success rate for discrete spontaneous episodes, as well as low implant complication rates.

Full Story: